Sanara MedTech (SMTI) to Release Earnings on Monday

Sanara MedTech (NASDAQ:SMTI – Get Rating) is scheduled to announce its earnings results after the market closes on Monday, May 16th. Investors that are interested in registering for the company’s conference call can do so using this link.

Shares of NASDAQ:SMTI opened at $22.04 on Monday. The company’s 50-day moving average is $26.88. Sanara MedTech has a 12-month low of $18.85 and a 12-month high of $43.89. The company has a market capitalization of $174.23 million, a PE ratio of -20.41 and a beta of 2.24.

SMTI has been the subject of several analyst reports. Zacks Investment Research upgraded Sanara MedTech from a “sell” rating to a “hold” rating in a report on Wednesday, February 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Sanara MedTech in a research note on Monday, May 2nd.

Several hedge funds have recently added to or reduced their stakes in SMTI. Royal Bank of Canada purchased a new stake in shares of Sanara MedTech during the second quarter worth about $74,000. Morgan Stanley raised its position in Sanara MedTech by 976.2% during the 3rd quarter. Morgan Stanley now owns 4,251 shares of the company’s stock valued at $146,000 after purchasing an additional 3,856 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Sanara MedTech in the 3rd quarter worth approximately $204,000. Finally, Susquehanna International Group LLP grew its position in shares of Sanara MedTech by 30.2% in the 4th quarter. Susquehanna International Group LLP now owns 16,800 shares of the company’s stock worth $511,000 after buying an additional 3,900 shares during the last quarter. Hedge funds and other institutional investors own 4.35% of the company’s stock.

About Sanara MedTech (Get Rating)

Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.

Read More